Short-term management of insomnia
Adult: 0.5-1.5 mg at bedtime.
Elderly: 0.5 mg at bedtime.
Elderly: 0.5 mg at bedtime.
Indications and Dosage
Oral
Short-term management of insomnia Adult: 0.5-1.5 mg at bedtime.
Elderly: 0.5 mg at bedtime. |
Administration
May be taken with or without food.
|
Contraindications
CNS depression; respiratory depression, acute pulmonary insufficiency or sleep apnoea; severe hepatic impairment; chronic psychosis, phobic or obsessional states; not to be used alone to treat depression or associated anxiety; unstable myasthenia gravis; glaucoma. Pregnancy and lactation, children
|
Special Precautions
Chronic pulmonary insufficiency; elderly or debilitated patients; muscle weakness, impaired liver or kidney function; personality disorders or organic brain changes; history of alcohol or drug addiction.
|
Adverse Reactions
Drowsiness and lightheadedness, muscle weakness and ataxia, vertigo, headache, confusion, depression, slurred speech, changes in libido, tremor, visual disturbances, urinary retention, GI disturbances, changes in salivation and amnesia.
|
Drug Interactions
Enhanced sedation or respiratory and CV depression with drugs with CNS depressant properties eg, antidepressants, antihistamines, antipsychotics, general anaesthetics, other hypnotics or sedatives, opioid analgesics and alcohol.
|
Action
Description: Lormetazepam is a short-acting benzodiazepine hypnotic.
Pharmacokinetics: Absorption: Readily absorbed from the GI tract. Metabolism: Metabolised to inactive glucuronide. Excretion: Terminal half life of around 11 hr. |
MIMS Class
|